India opens DCGI chief search as expanded eligibility draws regulator backlash
India has invited applications for the next Drugs Controller General of India, widening eligibility to include non-pharmacy engineering disciplines. Drug-control officers say the move could dilute technical oversight at a time when medicine quality and confidence in Indian-made drugs remain under scrutiny.
What happened
Central Drugs Standard Control Organisation (CDSCO) · India has opened applications for a new DCGI chief after expanding eligibility to non-pharmacy engineering
Key facts
- India's pharmaceutical market: $60 billion
- More than 140 global deaths linked to Indian-made cough syrups
- DCGI eligibility requires at least 15 years of experience
- AIDCOC represents over 3,000 regulatory officers
- Applicant upper age limit: 58 years
- Maximum deputation tenure: five years
- Application deadline: 30 September
- Raghuvanshi's extension runs until March 2027 or successor appointment
Why this matters
Acquirers and partners in Indian pharma should reassess regulatory diligence, as a new DCGI chief could alter compliance expectations and supply-chain oversight.
What to watch
- Final recruitment notification and any amendments narrowing or defining acceptable engineering disciplines.
- Identity, prior experience and stated priorities of the shortlisted or appointed candidate.
- Public objections, legal petitions or formal representations from drug-control officer associations.
- CDSCO inspection intensity, warning letters, recalls, approval-cycle times and staffing changes after the appointment.
- US FDA, EMA, WHO or major buyer actions involving Indian manufacturing sites.
- Evidence of procurement shifts toward firms with stronger compliance histories or diversified manufacturing footprints.
- Issue a detailed eligibility clarification emphasizing pharmaceutical manufacturing, quality assurance, clinical, toxicology and regulatory experience.
- Appoint an interim or acting DCGI if the recruitment process attracts objections or runs beyond the incumbent transition window.
- Increase visible inspections, recall actions and GMP enforcement to demonstrate continuity in medicine-quality oversight.
- Create a selection panel or advisory mechanism with drug-regulation and public-health experts to reduce credibility risk.
- Pharmaceutical exporters accelerate independent quality audits and documentation upgrades to reassure US, EU and other procurement customers.